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Abstract
Type 2 diabetes (T2D) is a disease whose occurrence is increasing prevalent in westernized civilizations and is responsible for the 
proliferation in the morbidity and total mortality of patients with cardiovascular diseases, worldwide. However, the complexity in 
the treatment and prevention of T2D arises from the intricacy of the many physical and biological factors involved in its etiology. 
Impaired pathways for insulin signaling have been implicated as one the many factors in the development of T2D Individual peroxisome 
proliferator-activated receptors (PPARs) have previously exhibited associations with alterations of lipid profiles, fat tissue and T2D and 
displayed complications derived from high levels of glucose. However, PPARgamma has not yet been associated with the development 
or developmental pathways of T2D. We performed an observational study a Spanish cohort in order to better understand the 
association between the SNP PPARgamma polymorphism Pro12Ala in our patients and the incidence of T2D and other cardiovascular 
complications. We study did not find a statistically significant relationship between the Pro12Ala and T2D development in our cohort, 
future observations will help us to know the association with vascular disease in patients with T2D.
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Introduction
Diabetes is a chronic disease with high prevalence in the 
world. It results when the pancreas does not produce enough 
insulin or when the body cannot effectively use the insulin 
produced. The etiology of the disease comprises many metabolic 
alterations (obesity, lipid profile, hypertension) that are too 
involved with a variable influence on the progression of the 
disease. Having access to directly influence diabetes, genetically, 
will greatly facilitate the proper therapeutic production and 
eventually prevention of disease complications, progression, 
and development.
As a complex disease, diabetes continues to elude the medical 
and research communities. However, and unfortunately, the 
growing pandemic incessantly enhances the gap between 
treatments and treated. The number of people worldwide 
with diabetes is projected to rise from 171 million in 2000 
to 366 million in 2030 [1]. In people over 65 years old the 
prevalence was 26.9% in 2007. Diabetes is a critical risk factor 
for cardiovascular disease. Consequently, the importance of 
diabetic cases a greatly augmented, as they relate to elevated 
morbidity and mortality. Patients’ vascular injury is accelerate 
due to their primary condition of diabetes, as previously reported, 
a total of 202,290 people were shown to need chronic dialysis 
or to be subjected to kidney transplantation a result of end-
stage kidney disease due to diabetes [2].
Type 2 Diabetes Mellitus (T2D), the most common type of 
diabetes (comprising 90% of patients worldwide), a complex 
metabolic disorder of multifactorial pathogenesis [3]. The genetic 
development of T2D is previously described [4]. The family of 
genes encoding the peroxisome proliferator-activated receptors 
(PPARs) are largely studied. The PPAR family of receptors are 
nuclear hormone receptors, which regulate lipid homeostasis 
and cellular differentiation and proliferation and modulate the 
immune response [5]. Activation of PPAR signaling pathways 
lead to an effect in lipid synthesis and oxidation, glucose 
uptake, inflammation, and expression of immunoregulatory 
genes [6]. As of yet three PPARs have been identified: PPAR-α, 
PPAR-δ and PPAR-γ.
The PPAR-γ gene is located on chromosome 3 (Loc. 3p25, 
OMIM 601487), contains 9 exons and spans more than 100 kb. 
PPAR-γ exists in two major protein isoforms (g1 and g2) and 
two minor forms (g3 and g4) created by alternate promoter 
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usage and alternative splicing at the 5´ end of the gene [8,9]. 
Yen et al., first identified a missense mutation resulting in the 
alanine substitution for proline at codon 12 (Pro12Ala) of the 
PPAR-γ gene (rs1801282) [10]. The structure and consequently 
the function of the protein may be affected by this amino acid 
change, since alanine favors the formation of the α-helix while 
proline prevents it. This polymorphism is located close to the 
NH2-terminus region of the protein, in the ligand-independent 
activation domain, and has been found to modulate the 
transcriptional activity of PPAR-γ. This activity is enhanced 
through phosphorylation by insulin [11,12]. PPAR-γ, is highly 
expressed in adipocytes, skeletal muscle, liver, and kidney, and 
has been shown to regulate expression of genes that mediate 
adipocyte differentiation, energy metabolism, and insulin 
action [7]. PPAR-γ activation improves insulin sensitivity and 
glucose, adiponectin, and fatty acid uptake [8].
Alterations in insulin signaling pathways play a central role 
in the pathogenesis of T2D. The Pro12Ala polymorphism leads 
to a diminished stimulation of PPAR-γ target genes, subsequent 
lowered levels of adipose tissue accumulation, which, in turn, 
may improve insulin sensitivity. We evaluated the allelic and 
genotypic distribution of the PPAR-γ Pro12Ala polymorphisms 
in two cohorts of patients, with and without diabetes from the 
Vascular Risk Unit of the University Hospital of Salamanca (UHS).
Materials and methods
Subjects
This observational study included 298 Caucasians living in the 
region of Salamanca, in central Spain (155 females, 70.3±13.6 
years old; 143 males, 74.0±12.6 years old). All subjects were 
selected from patients of the Vascular Risk Unit of the University 
Hospital of Salamanca. The individuals came from primary 
care centers to the control of hypertension, diabetes and/or 
other vascular risk factors. None of the patients had diagnosed 
vascular diseases. The patients were referred to the unit in 
order to participate in a program of the Vascular Risk Unit 
designed with the primary objectives to control vascular 
risk factors and follow the development of vascular disease 
over the subsequent five years, with an annual follow-up 
appointment. All subjects provided written informed consent, 
prior to entering the study. The protocol was approved by the 
ethics committee of the UHS following the Helsinki protocol.
Determination of patients with diabetes 
Diabetes mellitus was established in patients using two 
diagnostic criteria, according to the American Diabetes 
Association (ADA) [13,14], fasting (no food or drink for 12 
hr) blood glucose level greater than 126mg/dl, as well as 
glycosylated hemoglobin (HbA1c) level greater than 6.5%. 
The HbA1c average in men was 6.82% and in women was 
6.80%. The classification of patients resulted in having 77 
T2D subjects and 221 subjects without diabetes. This ration 
of subjects with and without T2D reflects the incidence of 
patients with alterations in glucose metabolism within the 
population residing in the surrounding region.
DNA extraction and genotyping
High molecular weight DNA was obtained from blood leukocytes, 
collected by venipuncture using a regular technique. DNA 
was isolated following standard procedures for Trizol reagent 
(Invitrogen, Carlsband, CA) extraction. The extracted DNA was 
stored at -80ºC until analyzed.
The analysis of the PPAR-γ Pro12Ala polymorphism (rs1799983) 
was performed through real-time PCR allelic discrimination. 
Our specified primers were commercially premixed with the 
TaqMan MGB® probe (C_1129864; Applied Biosystems, Foster 
City, California, USA). The TaqMan® Universal PCR Master Mix 
No AmpErase® UNG (Applied Biosystems, Foster City, Califronia, 
USA), containing DNA polymerase, was added to the prepared 
primer/probe mixture and analyses were carried out using 
an real-time PCR system (Applied Biosystems, Foster City, 
Califronia, USA). 
Statistical methods 
Logistic regression, including potential confounding factors 
age and sex as covariants, was applied to evaluate differences 
in allele and diploid genotype frequencies between subjects. 
A p-value ≤0.05 was regarded as significant. Odds ratios and 
95% confidence intervals (OR; 95% CI) were also calculated. 
The overall cohort size and statistical power was estimated 
according to the preliminary results obtained in this study, 
an estimate for 95% confidence intervals and 80% statistical 
power. All analyses were performed using the Statistical 
Package for Social Sciences (SPSS Inc, Chicago, Illinois, USA) 
version 19.20.
Results
The genotype distribution of the PPAR-γ Pro12Ala 
polymorphism was 88.23% (C/C), 10.85% (C/G) and 0.90% 
(G/G), in patients without diabetes, versus 80.51% (C/C), 19.49% 
(C/G) and 0.00% (G/G), in patients with T2D. Logistic regression 
analysis, used to compare genotypic frequencies between 
subject groups showed no significant differences, p=0.115. 
Discussion
Context and previous literature
Several studies exploring the relationship between the 
PPAR-γ Pro12Ala polymorphism and T2D, reportedly propose 
the Pro12Ala polymorphism as a strong candidate in the 
development of T2D [15], although the association between the 
metabolic disorder and the polymorphism is not consistently 
presented in the literature. Although previous studies in 
Caucasian populations published the Pro12Ala polymorphism 
does not correlate with the development of T2D [16,17], Gouda 
et al., conducted a meta-analysis involving 32,894 cases and 
47,456 controls from 60 studies [18], concluding that the 
PPAR-γ Pro12Ala polymorphism is positively associated with a 
reduction in the risk of T2D. Furthermore, the presence of other 
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vascular risk factors has also been explored in relation to the 
association between PPAR-γ and the onset of T2D. Similarly, 
other studies have demonstrated the PPAR-γ/T2D onset in 
association with Body Mass Index lipid profiles, also extending 
studies to secondary organ damage resulting from diabetes, 
diabetic nephropathy and coronary heart disease [19-22]. 
Advantages and limitations of this study
The majority of presently published observational studies 
have explored the Pro12Ala polymorphism in patients with 
T2D and its association with vascular risk factors and the 
development of stroke, heart failure, kidney damage, and/or 
other related vascular disease. However, a principal advantage 
of our study design is that we are able to monitor our subjects 
over time, gauging physical, biochemical, and epigenetic trait 
changes, enabling continuous examination of the interaction 
between Pro12Ala genotypes and the development of vascular 
complications.
As with most studies involving human subject, our examination 
presented the following limitations: (A) The subjects were 
selected from an outpatient clinic, specializing in vascular 
risks, rather than chosen randomly from the surrounding 
community; (B) We excluded patients currently receiving 
treatments to control diabetes or alter glucose levels; (C) 
Some of the subjects, may have possibly altered their habits 
after enrolling in the primary care program; (D) Some of our 
subjects may have maintained relatively healthy lifestyles, 
including healthy diet and/or exercise, which could affect 
the estimation of HbA1c levels. 
Conclusions and perspectives
We were unable to observe a significant correlation between 
the PPAR-γ Pro12Ala polymorphism and T2D in our Caucasian 
population, of Spanish descent. Consequently, we did not 
found a direct influence of the PPAR-γ Pro12Ala polymorphism 
genetic variation in the development of diabetes disease. 
However, we enrolled the patients in a longitudinal study to 
explore the Pro12Ala polymorphism and to check if it takes 
an active part in the pathophysiology of T2D onset,  through 
effects seen in adipose tissue, blood pressure, and vascular 
inflammation. Such effects increase the likelihood of 
developing vascular damage and long-term heart, brain, or 
kidney injury resulting from T2D in our cohort.
To ensure enhanced future treatment and preventative 
measures, the intricacies relating T2D and the PPAR-γ Pro12Ala 
polymorphism must be further explored, in the context 
of diabetic vascular complications, in varied populations 
worldwide. A greater understanding of the evolution of this 
disease will greatly diminish its devastating effects.
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